|Bid||22.00 x 3100|
|Ask||24.98 x 2200|
|Day's Range||23.00 - 23.97|
|52 Week Range||8.61 - 28.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.25|
Danforth Advisors, a Boston-area provider of financial and accounting services to the life sciences sector, has entered Pittsburgh. Founded in 2011, Danforth employs a team of consultants who are experienced accountants, corporate controllers and chief financial officers and specialists in financial planning and analysis. “Biotech companies are often pre-revenue stage and trying to build a business focused on science and getting things into the clinics,” said Robert Dickey IV, who joined Danforth last summer as managing director, Mid-Atlantic Region.
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-art Good Manufacturing Practice (GMP) facility, is complete. The new facility is located near the Company’s headquarters in Pittsburgh and will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). “Our development of internal manufacturing capabilities bolsters our position for commercial readiness as we execute on our vision to bring our therapies to the patient communities in need,” said Krish S Krishnan, chairman and chief executive officer of Krystal Biotech.
PITTSBURGH, Dec. 19, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PITTSBURGH, Nov. 20, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.
Krystal Biotech (KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported financial results for the third quarter ended September 30, 2018, and provided an update on the Company’s corporate progress. It is caused by mutations in the gene coding for type VII collagen, or COL7, a major component of the anchoring fibrils, which anchor the epidermis to the underlying dermis, and provide structural adhesion in a normal individual.
Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has closed the previously announced underwritten public offering of 3,000,000 shares of its common stock, at a public offering price of $20.00 per share. In addition, on October 19, 2018, the underwriters fully exercised their option to purchase an additional 450,000 shares of the Company’s common stock at the public offering price, less underwriting discounts. The gross proceeds to the Company from this offering were $69.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 25,000 shares of KRYS on 10/18/2018 at an average price of $20 a share.
NEW YORK , Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced that the firm is acting as lead manager in the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS), a gene ...
NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS) securities purchase agreement ...
Krystal Biotech, Inc. (KRYS) has been on the move lately as the stock has risen by 24.5% in the past four weeks, and it is currently trading well above its 20-Day SMA
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) ("Krystal"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On May 24, 2018, the Pennsylvania-based Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.